Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

OLIVER: GOOD MORNING. THIS IS BLOOMBERG DAYBREAK EUROPE. I’M OLIVER CROOK IN LONDON.THE YEN RALLIES AS JAPAN’S FINANCE MINISTER LEAVES THE DOOR OPEN FOR INTRERNTION. GOLD HITS ITS 50TH DAILY RECORD THIS YEAR. PRESIDENT TRUMP WARNS VENEZUELA’S PRESIDENT NICHOLAS MADURO BUT STOPS SHORT OF CALLING FOR HIS REMOVAL.AN APPROVAL TO SELL WEIGHT LOSS DRUG WEGOVY IN PILL FORM. HAPPY TUESDAY MORNING HERE. LOOKING AT THE FUTURES ACROSS EUROPE.NOT REALLY DOING A WHOLE LOT. EURO STOXX 50 FUTURES UNCHANGED AFTER A SLIGHTL ...

Core Insights - Novo Nordisk's shares surged after receiving FDA approval for an oral version of its weight loss drug Wegovy, expected to launch in January [1][7] - The oral formulation of semaglutide, the active ingredient in both Wegovy and Ozempic, represents a significant advancement in the GLP-1 class of drugs, which are already multibillion-dollar products [2][3] - The approval of the oral pill addresses patient convenience, as it eliminates the need for injections, making it more appealing to those averse to needles [4][5] Company Context - Novo Nordisk has faced a challenging year, with shares down approximately 53% from earlier highs in February, highlighting the need for a successful product launch [6] - The approval of the oral obesity pill is seen as a potential growth driver, but the successful execution of its commercial rollout will be crucial [7] - Novo Nordisk is in a competitive landscape, with Eli Lilly, its main rival, also working on an obesity drug expected to receive approval soon, emphasizing the urgency for Novo Nordisk to establish its market presence [8][9] Industry Dynamics - The oral formulation of obesity drugs is a new frontier in the pharmaceutical industry, with increasing interest from both established companies and startups [9] - Novo Nordisk faces competition not only from Eli Lilly but also from compounding pharmacies and emerging companies that are exploring the obesity market [9]

Core Viewpoint - Investors are optimistic about a potential buyout of Abivax by Eli Lilly, leading to a significant increase in Abivax's share price by nearly 21% [1][4]. Group 1: Acquisition Interest - Eli Lilly, a major American pharmaceutical company, is reportedly interested in acquiring Abivax, as indicated by a report from French periodical La Lettre [2]. - Eli Lilly representatives have met with French Treasury officials to understand the regulatory requirements for the acquisition [2]. - This speculation follows a previous surge in Abivax's stock price due to similar rumors, despite Eli Lilly's refusal to comment on such business development activities [4]. Group 2: Company Performance - Abivax's recent positive results from a Phase 3 clinical trial of its ulcerative colitis drug obefazimod have likely attracted Eli Lilly's interest [4]. - Abivax's current market capitalization stands at $9.0 billion, with a trading range of $130.14 to $139.62 for the day [6]. - The stock has shown a 52-week range from $4.77 to $139.62, indicating significant volatility and investor interest [6]. Group 3: Market Dynamics - Eli Lilly has a history of opportunistic acquisitions, as evidenced by its recent purchase of Adverum Biotechnologies to enhance its ophthalmology pipeline [6]. - Despite the positive sentiment, there are doubts about whether a deal would occur at a high premium due to the ongoing speculation surrounding Abivax [7].

Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly https://t.co/7qqZt3bFXY ...

Core Insights - The Trump administration has signed drug-pricing agreements with several large-cap drugmakers to lower drug prices in the U.S. [1] - The agreements require drugmakers to reduce prescription drug prices to match those in comparable developed countries, supporting the Most Favored Nation (MFN) pricing proposal [2] - Drugmakers will receive a three-year exemption from import tariffs on pharmaceutical ingredients in exchange for expanding domestic manufacturing operations [3] - Some companies will donate active pharmaceutical ingredients (APIs) to a government stockpile to ensure supply chain resilience during emergencies [4] - The Trump administration has now reached deals with 14 out of 17 targeted drug manufacturers, with three companies still in discussions [5] Industry Impact - The agreements address major concerns regarding drug pricing and tariffs, improving investor outlook for the pharmaceutical sector [6] - The deals are seen as a turning point that could alleviate regulatory and pricing pressures on the industry [7] - The latest agreements involve nine major drugmakers, joining others like Pfizer and AstraZeneca who signed similar deals earlier [8]

Core Viewpoint - Viking Therapeutics (NASDAQ:VKTX) is identified as a promising mid-cap healthcare stock with significant upside potential, projected at nearly 190% from its current price, with a target of $102 per share [1]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright analyst Joseph Pantginis has reaffirmed a Buy rating on Viking Therapeutics, forecasting a price target of $102 per share [1]. - Consensus estimates indicate a potential upside of over 176% for Viking Therapeutics, with a forecasted target price of $97.27, supported by all 13 analysts assigning Buy ratings [3]. Group 2: Product Development and Market Position - Viking Therapeutics focuses on differentiated VK2735 oral and injectable formulations, which are bolstered by positive outcomes from a Phase 3 study conducted by competitor Eli Lilly, showing oral therapies can effectively maintain weight loss previously associated with injections [2]. - The results from Eli Lilly's study validate Viking's ongoing oral obesity program, reducing commercial risks and increasing investor interest in the company [3]. - Viking Therapeutics specializes in therapies for metabolic and endocrine disorders, particularly targeting obesity, fatty liver, and diabetes through small-molecule drugs [4].

Market Overview - Wall Street's major equity averages ended positively, with Carnival (CCL) surging over +9% after better-than-expected Q4 adjusted EPS and above-consensus FY26 adjusted EPS guidance [2] - Chip stocks rallied, with Micron Technology (MU) climbing about +7% and Advanced Micro Devices (AMD) rising more than +6% [2] - Oracle (ORCL) advanced over +6% after signing agreements with TikTok and ByteDance for a new joint venture [2] - Nike (NKE) was the top loser on the Dow, plunging more than -10% due to expected sales drop amid weakness in China [2] Economic Indicators - U.S. existing home sales rose +0.5% month-over-month to a 9-month high of 4.13 million in November, but fell short of expectations [6] - The University of Michigan's consumer sentiment index for December was unexpectedly revised lower to 52.9, weaker than the expected 53.5 [6] Federal Reserve Insights - New York Fed President John Williams indicated no urgency to lower interest rates, citing recent jobs and inflation data [7] - Cleveland Fed President Beth Hammack expressed that there is no need to change interest rates for several months following recent cuts [8] - U.S. rate futures show an 80.1% chance of no rate change and a 19.9% chance of a 25 basis point cut at the Fed's January meeting [9] Upcoming Economic Data - Key U.S. economic data releases this week include the initial estimate of third-quarter GDP, Durable Goods Orders for October, and the Fed's industrial production reports for October and November [10] - The Commerce Department will only publish two readings for the third-quarter GDP due to a government shutdown [10] International Market Developments - The Euro Stoxx 50 Index is down -0.22%, with food and beverage stocks underperforming while mining and technology stocks advanced [12] - U.K. GDP growth was reported at +0.1% quarter-over-quarter and +1.3% year-over-year, in line with expectations [13] - Japan's Nikkei 225 Stock Index closed sharply higher, buoyed by a weaker yen and Wall Street's rally [15]

Group 1: Drug Pricing Agreements - President Trump announced "historic" drug pricing agreements with nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, aimed at reducing prices for Medicaid and direct-to-consumer sales through TrumpRx.gov [2][3] - The agreements are intended to align U.S. drug costs with the lowest prices paid by other developed nations, a concept known as "most-favored-nation" pricing [2] Group 2: Market Reactions to Drug Pricing - Despite the price cuts, pharmaceutical stocks saw gains, with GSK rising 1%, Merck gaining 1%, and Gilead Sciences surging approximately 3% [3] - The rally in stock prices is attributed to tariff exemptions secured by these companies in exchange for their pricing agreements, which alleviated potential tariff burdens [3][4] Group 3: Tariff Impacts - The U.S. effective tariff rate increased from 2.4% to 16.8%, the highest since 1935, contradicting claims that tariffs would reduce costs [5] - Market reactions to tariff announcements have been volatile, with significant drops in major indices following threats of tariff increases, such as a 2.7% decline in the S&P 500 on October 11, 2025 [6][8] Group 4: Economic Analysis of Tariffs - Analysts from Goldman Sachs warned that increased tariffs could significantly impact growth, estimating a reduction of nearly 0.7 percentage points from China's growth in 2025 [8] - The Tax Foundation labeled Trump's tariffs as the "largest tax hike since 1993," estimating an average increase of $1,100 per U.S. household in 2025 [8] Group 5: Warrior Dividend Announcement - President Trump announced a "$1,776 'warrior dividend'" for U.S. military personnel, funded by tariffs, totaling an estimated $2.6 billion [9][10] - Reports clarified that these payments were not new funds from tariffs but repurposed from existing military housing supplements, indicating a rebranding of existing funds rather than a new financial initiative [10][11] Group 6: Overall Economic Environment - The unpredictable nature of Trump's economic policies has led to erratic market behavior, with investors needing to navigate through rhetoric and actual economic impacts [12] - The combination of drug pricing agreements, tariff threats, and the warrior dividend illustrates the complex interplay of policy and market reactions in the current economic landscape [12]

Group 1 - Palantir (PLTR) and Willdan Group (WLDN) have recently broken out of traditional bases, indicating new investment opportunities as they trade above buy points [5] - The Nasdaq composite has climbed back above the 50-day moving average, suggesting a recovering stock market [5] - Oracle's stock has jumped following reports that TikTok signed a deal to create a U.S. joint venture, highlighting potential growth in tech partnerships [7] Group 2 - The focus is on tech stocks as the market shows bullish signs, with Palantir and GE leading 12 stocks currently in buy zones [8] - The S&P 500 and Nasdaq have rallied due to a favorable inflation report, benefiting AI leaders and other tech stocks [10] - Companies like AppLovin and Eli Lilly are also in focus as the market reacts to recent developments [10]